Metomylan

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metomylan

Quick Facts

Characteristic Detail
Active Ingredient Metoprolol
Drug Class Selective beta1-Blocker (Beta-blocker)
Primary Uses Hypertension, Angina Pectoris, Heart Failure, Post-Myocardial Infarction

Metomylan is a brand name for a medication containing the active substance metoprolol. This drug belongs to a class of medicines known as selective beta-blockers.

Mechanism of Action

Metoprolol primarily targets and blocks the beta1-adrenergic receptors, which are mainly located in the heart. This action is referred to as cardioselective antagonism. By blocking these receptors, metoprolol lessens the effects of stress hormones like adrenaline and noradrenaline on the heart. The result is a reduction in heart rate and force of contraction, which lowers blood pressure and decreases the heart's overall oxygen demand.

Medical Uses

Metomylan is prescribed to treat several cardiovascular conditions. Its primary approved uses include:

  • Hypertension (high blood pressure): To lower blood pressure and reduce the risk of associated cardiovascular events like stroke or heart attack.
  • Angina Pectoris: For the long-term management and prevention of chest pain caused by reduced blood flow to the heart.
  • Myocardial Infarction (Heart Attack): To reduce the risk of cardiovascular mortality following a heart attack in hemodynamically stable patients.
  • Stable Chronic Heart Failure: Used in combination with other medications to improve outcomes and reduce hospitalization.

Metoprolol is available in different salt forms, such as metoprolol tartrate (often immediate-release) and metoprolol succinate (often extended-release), which affect dosing frequency and duration of action. The form prescribed depends on the condition being treated and the patient's specific needs.

What side effects are possible with Metomylan?

Metomylan is generally well-tolerated, but like all medications, it can cause side effects. These often lessen as your body adjusts to the drug.

Common Side Effects

Common side effects, which may occur in a number of patients, are typically mild and include:

  • Dizziness or lightheadedness, particularly when standing up quickly (orthostatic hypotension).
  • Fatigue or unusual weakness.
  • Diarrhea or constipation.
  • Headache.
  • Electrolyte imbalances, such as low potassium (hypokalemia) and low sodium (hyponatremia).

Regular blood tests are necessary to monitor your electrolyte and kidney function while taking this medication.

Serious Side Effects

While rare, more serious adverse effects may require immediate medical attention. Contact your healthcare provider right away if you experience:

  • Signs of a severe allergic reaction, such as hives, rash, swelling of the face, throat, or tongue, or difficulty breathing.
  • Dehydration symptoms, including excessive thirst, very dry mouth, or greatly decreased urination.
  • Worsening signs of heart failure, such as sudden weight gain, increased shortness of breath, or swelling in the feet or ankles.
  • Symptoms of a severe skin reaction, like blistering, peeling skin, or painful sores.
  • Liver problems, indicated by yellowing of the skin or eyes (jaundice), dark urine, or upper right abdominal pain.

Safety Precautions and Warnings

This medication is contraindicated in patients with anuria (inability to produce urine) or severe liver failure. Caution is advised for individuals with diabetes, gout, or certain types of kidney disease, as Metomylan may worsen these conditions or mask symptoms like those of low blood sugar.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information for metoprolol overdose describes serious and potentially life-threatening physiological effects that necessitate immediate medical attention.

Documented Overdose Manifestations

Symptoms officially documented in prescribing information typically involve severe beta-blockade effects, including profound bradycardia (abnormally slow heart rate) and hypotension (severely low blood pressure). Additional manifestations include vomiting, significant impaired consciousness, and bronchospasm. Severe outcomes documented in regulatory sources can escalate to cardiogenic shock, cardiac arrest (asystole), and high-degree atrioventricular (AV) block.

Severe Regulatory Note Complications or Special Considerations
Life-Threatening Risk Documented risk of pulmonary edema and metabolic acidosis following overdose.
Population Risk Children face an increased risk of severe hypoglycemia (low blood sugar), which can lead to nervous system symptoms.

Required Emergency Actions

Regulatory guidance explicitly mandates to seek immediate medical attention for any suspected overdose and to contact emergency services immediately. Hospitalization and continuous cardiovascular monitoring are required for management. Treatment is documented as symptomatic and supportive, utilizing specific interventions like Atropine or Glucagon to counteract the beta-blocking effects. No specific antidote is known.

Therapeutic Uses of Metomylan

What Metomylan Treats: Main Uses and Benefits

This medication is generally used to help manage symptoms related to cardiovascular strain.

Metomylan is applied across several therapeutic domains, including high blood pressure (hypertension), chronic chest pain (stable angina), and supportive management following a heart attack. It is relevant for easing symptoms that interfere with daily functioning. For individuals with chronic heart conditions, the therapeutic aim is to provide supportive relief.

The medication plays a role in managing symptoms that create noticeable physiological strain, helping patients cope more steadily with symptom fluctuations. This supportive role is captured by the sentiment:

“The therapy is relevant when supportive symptom management is appropriate and contributes to improved comfort during symptomatic periods.”

The medication may also be part of symptomatic management for conditions involving episodic or fluctuating manifestations, such as certain types of migraine headaches. It can help address symptom clusters that interfere with daily comfort.

Quick Fact: Symptomatic Support
Supports general well-being by easing physical discomfort associated with chronic chest pain.

Eligibility and Restrictions for Use

Metomylan (metoprolol) is a beta-blocker primarily used to treat several cardiovascular conditions. It is an approved treatment for high blood pressure (hypertension), angina pectoris (chest pain), and to reduce the risk of cardiovascular events following a heart attack (myocardial infarction). It is also prescribed to manage chronic heart failure and certain types of irregular heart rhythm.


Contraindications (Who Should Not Use Metomylan)

Metomylan is not suitable for everyone and is generally contraindicated in patients with the following severe or acute medical conditions:

  • Severe Bradycardia (very slow heart rate).
  • Second- or Third-Degree Heart Block (a severe delay in electrical signals in the heart) without a permanent pacemaker.
  • Decompensated Heart Failure (unstable or acutely worsening heart failure).
  • Cardiogenic Shock (a life-threatening condition where the heart cannot pump enough blood).
  • Sick Sinus Syndrome (a heart rhythm disorder) unless a pacemaker is in place.
  • Known Hypersensitivity or Allergic Reaction to metoprolol or other beta-blockers.

Important Considerations

Use of Metomylan requires careful monitoring in patients with pre-existing conditions such as asthma or other severe breathing disorders, diabetes, liver disease, or certain peripheral vascular diseases (poor circulation in the limbs). It is crucial to inform your healthcare provider about all current health conditions before starting this medication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Metomylan (Metoprolol) interacts with several other medicines and substances, primarily due to its metabolism and its effects on the cardiovascular system. This information is based on authoritative regulatory labeling and is not clinical advice.

Pharmacokinetic Interactions (Metabolism)

Metomylan is mainly metabolized by the CYP2D6 enzyme. Co-administration with strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine) significantly increases Metomylan blood concentrations and its effects. Conversely, enzyme inducers (e.g., rifampicin) may decrease its concentration.

Pharmacodynamic Interactions

Concurrent use with other medications that slow heart rate or decrease blood pressure can result in additive effects:

  • Calcium Channel Blockers (e.g., diltiazem, verapamil) may potentiate effects on heart rate, blood pressure, and AV conduction. Intravenous administration of verapamil is generally contraindicated.
  • Digitalis Glycosides (e.g., digoxin) and Antiarrhythmic Agents may increase the risk of excessive bradycardia.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the blood pressure-lowering effect of Metomylan.

Other Documented Interactions

  • Clonidine: If combination therapy is stopped, Metomylan must be gradually withdrawn several days before Clonidine to prevent severe rebound hypertension.
  • Food: The absorption of the immediate-release formulation is increased when taken with food.
  • Epinephrine: Patients on Metomylan may be unresponsive to standard doses of Epinephrine used for allergic reactions.

Mechanism of Action

The pharmacological action of Metomylan is mediated by its primary role as a selective beta1-adrenergic receptor antagonist (beta-blocker). The drug is considered cardioselective due to its preferential binding to beta1 receptors, which are predominantly located in the cardiac tissue, compared to beta2 receptors found in the vasculature and bronchi.

Metomylan competitively inhibits the binding of endogenous catecholamines, such as adrenaline (epinephrine) and noradrenaline (norepinephrine), to the beta1 receptors on the surface of cardiac cells. This blockade prevents the subsequent activation of intracellular signaling pathways involving cyclic AMP (cAMP) and protein kinase A (PKA).

This molecular cascade results in negative chronotropic and negative inotropic effects. The reduction in sympathetic stimulation decreases the rate of spontaneous depolarization in the sinoatrial node and slows conduction velocity through the atrioventricular node, thereby reducing the heart rate. Furthermore, the inhibition of PKA-mediated calcium influx into ventricular myocytes decreases the force of cardiac muscle contraction. These actions ultimately lead to a decrease in cardiac output and myocardial oxygen demand.

Dosage and Administration Information

How to Use Metomylan

This section outlines the standardized usage procedures for Metomylan (metoprolol), detailing administration, dosing principles, and preparation requirements.


Administration and Dosage Forms

Metomylan is administered through two routes: Oral (tablet or capsule) for chronic therapy and Intravenous (IV) Injection for immediate, short-term use in acute settings. The dosage form dictates the dosing pattern:

Formulation Type Salt Form Frequency Pattern
Immediate-Release (IR) Tablets Metoprolol Tartrate Multiple times daily
Extended-Release (ER) Tablets/Capsules Metoprolol Succinate Once daily

Official Dosing Principles

Dosing regimens are highly specific to the indication and formulation. For chronic conditions like hypertension and angina, the medicine is initiated at a low dose and gradually adjusted at intervals of one week or longer. For stable chronic heart failure (using the ER form), the dose is typically doubled every two weeks up to the maximum tolerated dose.

Key Administration Instructions

  • Timing with Food: Oral formulations must be taken consistently with a meal or immediately after a meal to maintain predictable absorption.
  • ER Handling: Extended-release tablets must be swallowed whole or as scored halves, and must not be crushed or chewed. If using ER capsules, the contents may be sprinkled on soft food (like applesauce) and consumed within 60 minutes.
  • Discontinuation: If treatment must be stopped, the dosage must be gradually reduced over a period of 1 to 2 weeks. Abrupt cessation is advised against to avoid procedural complications.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Key Findings on Investigation and Activity

The core evidence describes the medication's focus in research. This activity was evaluated in studies as an option for chronic conditions.

In all major clinical trials, the medication was investigated for its activity compared to placebo. Studies have evaluated the time course of the observed effects, with trial periods lasting up to 12 weeks. Results from these trials are used to describe the findings of the medication’s investigation.


Clinical Data Summary

Research has explored varying treatment methods for patients showing limited initial response. The studies investigated whether the combination affected patient reported data compared to monotherapy.

The majority of studies evaluated a safety profile that was observed in the research.

Trial results documented tolerability in participants who were evaluated in the research. The studies primarily evaluated a specific patient population, and certain groups were not included.

Frequently Asked Questions (FAQ)

Common questions about Metomylan (FAQ)


Q: Is Metomylan considered a long-term treatment option?

According to official product information, treatment with metoprolol is commonly described as a long-term option, especially for chronic conditions like high blood pressure and stable heart failure. The medication is typically used on a long-term basis as determined by a healthcare provider.

Q: How quickly does Metomylan usually begin to work?

For the purpose of reducing blood pressure, studies and official information indicate that the maximum effect of any given dosage level is generally apparent after one week of therapy.

Q: Is a headache a normal side effect when starting Metomylan?

Headache is listed in regulatory documents as a common adverse reaction to this medication, meaning it is seen in 1% to 10% of patients. The regulatory document does not specify if the common side effect of headache is particularly associated with the initiation phase of therapy.

Q: Are there any major food or drink items I should avoid with Metomylan?

Official drug information reports that the use of metoprolol with alcohol (ethanol) may lead to altered medication effects. While the medication is meant to be taken with food, specific major food items to avoid are generally not listed in the main warnings.

Q: Can Metomylan interact with supplements like vitamins or herbal products?

Metoprolol is primarily processed by a liver enzyme called CYP2D6. Therefore, any supplement, vitamin, or herbal product that strongly affects this enzyme may either increase or decrease the concentration and effects of Metomylan in the body. Official guidance notes that metabolic interactions are a point of consideration when discussing this medication with a healthcare provider.

Q: Can elderly patients use Metomylan?

Metoprolol is generally used in the elderly population. Official sources note that age-related conditions affecting the liver, kidney, or heart are more likely in older individuals. Official information suggests that specific consideration for the prescribing regimen may be necessary in these cases.

Q: Can Metomylan be taken by people with kidney problems?

The dosage does not typically require change for people with mild to moderate kidney impairment. However, official prescribing guidelines indicate that for those with severe kidney impairment, specific consideration is required for the starting regimen.

Q: How long does Metomylan stay in your system?

According to official pharmacokinetic data, the mean elimination half-life of metoprolol is typically 3 to 4 hours.

Q: How is Metomylan eliminated from the body?

Metoprolol is eliminated mainly by a process called biotransformation, which takes place in the liver. This process primarily involves a liver enzyme known as CYP2D6.

Q: Does long-term use of Metomylan have different risks than short-term use?

Evidence from clinical data indicates that with long-term use, some patients may notice certain side effects that persist or develop, such as persistent or worsening fatigue, weight gain, or mood changes like worsening depression. This type of information is used to help describe the safety profile of the medication.

Q: Does Metomylan cause weight gain or weight loss?

Clinical findings summarized by authoritative sources indicate that some beta-blockers, including metoprolol, may be associated with weight gain. This effect is usually modest, often occurring within the first few months of treatment, and typically stabilizes over time.

Q: Can Metomylan affect my sleep or cause insomnia?

Yes, regulatory documents list insomnia (difficulty sleeping) and other sleep disturbances as uncommon side effects of this medication, meaning they are seen in 0.1% to 1% of patients.

Q: Is it safe to drink alcohol while using Metomylan?

Official drug information generally notes that the use of metoprolol with ethanol (alcohol) is associated with the possibility of altered medication effects.

Q: Is Metomylan appropriate for children or adolescents?

Metoprolol is approved for pediatric patients 6 years of age and older for the treatment of hypertension (high blood pressure). Use in children younger than 6 years is not specifically included in the general regulatory labeling.

Q: Can Metomylan be used during pregnancy, based on official information?

Official labeling designates metoprolol as Pregnancy Category C. This is based on animal studies that have shown potential adverse effects on the fetus, and the fact that there are no adequate and well-controlled studies in humans to definitively assess risk.

Q: Is Metomylan available as a generic medicine?

Yes, according to the official FDA database for generic drugs, regulatory agencies have approved generic versions of both the immediate-release metoprolol tartrate and the extended-release metoprolol succinate formulations.

Q: Is Metomylan a controlled substance?

No, official classifications from relevant government agencies indicate that metoprolol is not classified as a controlled substance under the Controlled Substances Act.

Q: Can Metomylan cause vision changes?

Official regulatory information lists visual disturbance, such as blurred vision, as a rare side effect of the medication.

Q: What is the relationship between Metomylan and mood changes?

Regulatory documents list depression as a common side effect (1% to 10% incidence). Very rarely, more severe central nervous system effects such as confusion or hallucination have also been reported.

Q: Can Metomylan cause skin sensitivity to the sun?

Studies and regulatory labeling report that increased sensitivity of the skin to sunlight (photosensitivity) and severe sunburn are listed as rare side effects of Metomylan.

Q: Is Metomylan known to cause dry mouth?

Yes, dry mouth is listed in official consumer and drug information as a possible side effect of metoprolol.

Q: What are the symptoms of an overdose of Metomylan?

According to official prescribing information, symptoms of an overdose may include severe low blood pressure, slow heart rate, heart rhythm changes, and in severe cases, nausea, vomiting, and loss of consciousness.

How should Metomylan be stored and disposed of?

How to Store and Dispose of Metomylan

Metomylan (metoprolol) must be stored at controlled room temperature, which is between 68 F and 77 F (20 C and 25 C). The official labeling permits temperature excursions between 59 F and 86 F (15 C and 30 C). The tablets must be kept in the original container, tightly closed, and protected from light and moisture to maintain product stability.

Handling and Disposal

It is a mandatory requirement to store the medication out of the sight and reach of children. For disposal, unused or expired Metomylan should be discarded according to local regulatory requirements or through an authorized drug take-back program. If no take-back program is available, the tablets may be mixed with an undesirable substance, placed in a sealed bag, and thrown into the household trash, after scratching out all identifying information on the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metomylan found in:

A-Z Index: